237 related articles for article (PubMed ID: 31145074)
41. Cutaneous lupus associated with pembrolizumab therapy for advanced melanoma: a report of three cases.
Blakeway EA; Elshimy N; Muinonen-Martin A; Marples M; Mathew B; Mitra A
Melanoma Res; 2019 Jun; 29(3):338-341. PubMed ID: 30762712
[TBL] [Abstract][Full Text] [Related]
42. Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors.
Zarbo A; Belum VR; Sibaud V; Oudard S; Postow MA; Hsieh JJ; Motzer RJ; Busam KJ; Lacouture ME
Br J Dermatol; 2017 Jun; 176(6):1649-1652. PubMed ID: 27943234
[TBL] [Abstract][Full Text] [Related]
43. Two cases of clinical myasthenia gravis associated with pembrolizumab use in responding melanoma patients.
Nguyen BH; Kuo J; Budiman A; Christie H; Ali S
Melanoma Res; 2017 Apr; 27(2):152-154. PubMed ID: 27776019
[TBL] [Abstract][Full Text] [Related]
44. Presence of antibodies to striated muscle and acetylcholine receptor in association with occurrence of myasthenia gravis with myositis and myocarditis in a patient with melanoma treated with an anti-programmed death 1 antibody.
Shirai T; Kiniwa Y; Sato R; Sano T; Nakamura K; Mikoshiba Y; Ohashi N; Sekijima Y; Okuyama R
Eur J Cancer; 2019 Jan; 106():193-195. PubMed ID: 30528803
[No Abstract] [Full Text] [Related]
45. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.
Hamid O; Puzanov I; Dummer R; Schachter J; Daud A; Schadendorf D; Blank C; Cranmer LD; Robert C; Pavlick AC; Gonzalez R; Hodi FS; Ascierto PA; Salama AKS; Margolin KA; Gangadhar TC; Wei Z; Ebbinghaus S; Ibrahim N; Ribas A
Eur J Cancer; 2017 Nov; 86():37-45. PubMed ID: 28961465
[TBL] [Abstract][Full Text] [Related]
46. Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma.
Petrella TM; Robert C; Richtig E; Miller WH; Masucci GV; Walpole E; Lebbe C; Steven N; Middleton MR; Hille D; Zhou W; Ibrahim N; Cebon J
Eur J Cancer; 2017 Nov; 86():115-124. PubMed ID: 28987768
[TBL] [Abstract][Full Text] [Related]
47. Antiprogrammed Cell Death-1 Immunotherapy-Related Secondary Sclerosing Cholangitis.
Ogawa K; Kamimura K; Terai S
Hepatology; 2019 Feb; 69(2):914-916. PubMed ID: 30033637
[No Abstract] [Full Text] [Related]
48. [Alopecia areata under ipilimumab].
Amini-Adle M; Dalle S
Ann Dermatol Venereol; 2018; 145(6-7):465-466. PubMed ID: 29653853
[No Abstract] [Full Text] [Related]
49. Coincident Metastatic Melanoma and Merkel Cell Carcinoma with Complete Remission on Treatment with Pembrolizumab.
Thiem A; Kneitz H; Schummer P; Herz S; Schrama D; Houben R; Goebeler M; Schilling B; Gesierich A
Acta Derm Venereol; 2017 Nov; 97(10):1252-1254. PubMed ID: 28761962
[No Abstract] [Full Text] [Related]
50. [Toxic epidermal necrolysis due to anti-PD1 treatment with fatal outcome].
Demirtas S; El Aridi L; Acquitter M; Fleuret C; Plantin P
Ann Dermatol Venereol; 2017 Jan; 144(1):65-66. PubMed ID: 28011090
[No Abstract] [Full Text] [Related]
51. Drug-associated vasculitis occurring after treatment with pembrolizumab.
Tolaymat OA; Pinkston O; Wang B; Schenk WB; Joseph RW; Mergo PJ; Berianu F
Rheumatology (Oxford); 2019 Aug; 58(8):1501-1503. PubMed ID: 30892627
[No Abstract] [Full Text] [Related]
52. [Grover's-like drug eruption under anti-PD-1 therapy for metastatic melanoma].
Amini-Adle M; Balme B; Dalle S
Ann Dermatol Venereol; 2018 Dec; 145(12):802-803. PubMed ID: 30415933
[No Abstract] [Full Text] [Related]
53. Generalised morphea induced by pembrolizumab.
Herrscher H; Tomasic G; Castro Gordon A
Eur J Cancer; 2019 Jul; 116():178-181. PubMed ID: 31202088
[No Abstract] [Full Text] [Related]
54. Management of Chronic Hypotony Following Bilateral Uveitis in a Patient Treated with Pembrolizumab for Cutaneous Metastatic Melanoma.
Reid G; Lorigan P; Heimann H; Hovan M
Ocul Immunol Inflamm; 2019; 27(6):1012-1015. PubMed ID: 29672247
[No Abstract] [Full Text] [Related]
55. Pembrolizumab-induced necrotic myositis in a patient with metastatic melanoma.
Vallet H; Gaillet A; Weiss N; Vanhaecke C; Saheb S; Touitou V; Franck N; Kramkimel N; Borden A; Touat M; Ricard D; Verny M; Maisonobe T; Psimaras D
Ann Oncol; 2016 Jul; 27(7):1352-3. PubMed ID: 26940685
[No Abstract] [Full Text] [Related]
56. Long-term adverse event: inflammatory orbitopathy induced by pembrolizumab in a patient with metastatic melanoma.
Nardin C; Borot S; Beaudoin MA; Cattin F; Puzenat E; Gauthier AS; Schillo F; Borg C; Aubin F
Invest New Drugs; 2019 Apr; 37(2):375-377. PubMed ID: 30145624
[TBL] [Abstract][Full Text] [Related]
57. Pembrolizumab-associated mucous membrane pemphigoid in a patient with Merkel cell carcinoma.
Haug V; Behle V; Benoit S; Kneitz H; Schilling B; Goebeler M; Gesierich A
Br J Dermatol; 2018 Oct; 179(4):993-994. PubMed ID: 29758087
[No Abstract] [Full Text] [Related]
58. Pembrolizumab-Related Enophthalmos.
Manta A; Goldberg RA
Ophthalmology; 2020 Jan; 127(1):121. PubMed ID: 31864472
[No Abstract] [Full Text] [Related]
59. Definite regression of cutaneous melanoma metastases upon addition of topical contact sensitizer diphencyprone to immune checkpoint inhibitor treatment.
Gulati N; Carvajal RD; Postow MA; Wolchok JD; Krueger JG
Exp Dermatol; 2016 Jul; 25(7):553-4. PubMed ID: 27061281
[No Abstract] [Full Text] [Related]
60. A case of multiple immune toxicities from Ipilimumab and pembrolizumab treatment.
Humayun MA; Poole R
Hormones (Athens); 2016 Apr; 15(2):303-306. PubMed ID: 27376434
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
